The federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,480,488 to Brigham & Women's Hospital Inc. to research the combination of mRNA nanotherapy with standard antiangiogenic/immunotherapy for hepatocellular carcinoma (HCC). The research project runs from September 1, 2023 to August 31, 2026. As part of this effort, Massachusetts General Hospital will conduct preclinical studies to evaluate the antitumor efficacy and survival of the mRNA nanotherapy combined with immunotherapeutic agents in HCC models with underlying liver damage. The collaboration will also investigate the memory immune responses and validate the immunological memory of this combination therapy approach.
Generated 5/14/24, 2:42 AM